期刊文献+

市售3种富马酸替诺福韦二吡呋酯片的主要质量比较 被引量:2

Main Quality Comparison of Tenofovirdisoproxil Fumarate Tables Produced by Different Manufacturers
下载PDF
导出
摘要 目的:对市售的3厂家生产的富马酸替诺福韦二吡呋酯片的主要质量指标进行比较。方法:依据CFDA批准的该片质量标准,采用高效液相色谱法(HPLC-UV),选择苯基键合硅胶色谱柱(Inertsil Phenyl-3柱),使用梯度洗脱的方式测定该片的主药含量和有关物质;采用紫外-可见分光光度法测定溶出度。结果:3厂家(代号A、B、C)生产的片剂主药含量和有关物质均均符合标准要求;在0.01 mol·L^(-1)盐酸、0.1 mol·L^(-1)盐酸、pH 4.5醋酸盐缓冲液、pH 6.8磷酸盐缓冲液和纯化水中,30 min内3个产品均完全溶出。国产品种B的主药含量最高,有关物质相对最低,C产品在20 min内溶出较慢。结论:3厂家测定批次的富马酸替诺福韦二吡呋酯片的主药含量、有关物质和溶出度均符合规定,B产品对主要质量指标的控制相对更为严格。 Objective: To compare the qualities of three products of tenofovirdisoproxil fumarate tables supplied by different manufactories. Methods: The content of tenofovirdisoproxil fumarate and related substances were determined by HPLC with an Inertsil Phenyl-3 column(gradient elution), and the dissolution was determined by UV-Vis spectrophotometry. Results: The contents of all tenofovirdisoproxil fumarate tables were more than 90%. The contents of related substances of them were all lower than the limits specified in the standard of the State Food and Drug Administration, among which the domestic "Product B" had a more stringent control for the main content and the related substances. Complete dissolution was observed in 0.01 mol·L^(-1) HCl, 0.1 mol·L^(-1) HCl, pH4.5 acetate, pH6.8 phosphate buffer and purified water within 30 min for all of the tenofovirdisoproxil fumarate tables, and the slowest dissolution was found for "Product C" within 20 min. Conclusions: The main drug content, related substance and dissolution of tenofovirdisoproxil fumarate tables produced by different companies all comply with the quality standard, but there exist variations. It seems that the quality of domestic "Product B" was better.
作者 田慈惠 刘航岐 杨柳 张梅 黄林 肖衍宇 TIAN Cihui;LIU Hangqi;YANG Liu;ZHANG Mei;HUANG Lin;XIAO Yanyu(College of Pharmacy,China Pharmaceutical University,Nanjing 210009,China)
出处 《药学与临床研究》 2018年第3期175-178,共4页 Pharmaceutical and Clinical Research
关键词 富马酸替诺福韦二吡呋酯片 高效液相色谱法 含量 有关物质 溶出度 Tenofovirdisoproxil fumarate tables HPLC Content Related substance Dissolution
  • 相关文献

参考文献2

二级参考文献31

  • 1崔岚,安富荣,王晓珉.核苷酸逆转录酶抑制剂替诺福韦DF[J].中国新药杂志,2004,13(11):1054-1058. 被引量:30
  • 2BHATTACHARYA D, THIO CL. Review of hepatitis B therapeutics[J]. Clin Infect Dis, 2010, 1 (10) : 1201 - 1208.
  • 3GISH R, JIA JD, LOCARNINI S,et al. Selection of chronic hepatitis B therapy with high barrier to resistance [ J]. Lancet Infect Dis,2012,12(4) : 341 -353.
  • 4DECHRISTOFORO R, PENZAK SR. Tenofovir: a nucleotide anaXogue reverse-transcriptase inhibitor for treatment of HIV infection[ Jl .Am J Health Syst Pharm,2004,61 ( 1 ) :86 -98.
  • 5BUTI M ,HOMS M. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B [ J ]. Expert Rev Gastroenterol Hepatol, 2012,6(4) :413 -421.
  • 6LIAW YF, SHEEN IS, LEE CM,et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease[ J ]. Hepatology, 2011,53 ( 1 ) :62 - 72.
  • 7LOK AS, MCMAHON BJ. Chronic hepatitis B: update 2009 [ J ]. Hepatology, 2009,50 ( 3 ) :661 - 662.
  • 8MARCELLIN P, HEATHCOTE EJ, BUTI M,et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B [ J ]. N Engl J Med,2008,359 (23) :2442 - 2455.
  • 9"FAN J, DEGERTEKIN B, WONG SN,et al. Tenofovir monotherapy is effective treatment failure Toadefovir in the absence of adefovir-resistant mutations[ J]. J Hepatol, 2008,48(3):391 -398.
  • 10BERG T, MARCELLiN P, ZOULIM F,et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection [ J ]. Gastroenterology, 2010, 139(4) :1207 - 1217.

共引文献15

同被引文献18

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部